Risk factors of pneumonitis following chemoradiotherapy for lung cancer

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 71-75

  Yamada, M ^a   Kudoh, S ^a   Hirata, K ^a   Nakajima, T ^a   Yoshikawa, J ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Irinotecan; Lung cancer; Multivariate analysis; Pneumonitis; Radiation therapy; Risk factor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; VINDESINE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LUNG CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; RADIATION INJURY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY FIBROSIS; RADIATION PNEUMONITIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0031913009     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00377-8     Document Type: Article

References (30)

1. 1. Strauss GM, Lanter MP, Elias AD, Skarin AT, Sugarbaker D. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: A critical review of the literature and strategies for future research. J Clin Oncol 1992, 10, 829-838.
2. 2. Hazuka MB, Turrisi AT. The evolving role of radiation therapy in the treatment of locally advanced lung cancer. Semin Oncol 1993, 20, 173-184.
3. 3. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a metaanalysis. Ann Intern Med 1996, 125, 723-729.
4. 4. Warde P, Payne DP. Does thoracic irradiation improve survival and local control in limited small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992, 10, 890-895.
5. 5. Johnson DH, Arriagada R, Ihde D, et al. Meta-analysis of randomized trials evaluating the role of thoracic radiotherapy in limited stage small cell lung cancer (abstract). Proc Am Soc Clin Oncol 1992, 11, 288.
6. 6. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982, 9, 34-51.
7. 7. Stoaver DE. Pulmonary toxicity. In Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 4th edn. Philadelphia, JB Lippincott Co., 1993, 2362-2370.
8. 8. Roach M, Phillips TL. Pulmonary toxicity. In John MJ, Flam MS, Legha SS, et al., eds. Chemoradiation: An Integrated Approach to Cancer Treatment. Malvem, PA, Lea & Febiger, 1993, 444-459.
9. 9. Gibson PG, Bryant DH, Morgan GW, et al. Radiation-induced lung injury: a hypersensitivity pneumonitis? Ann Intern Med 1988, 109, 288-291.
10. 10. Roberts MC, Foulcher E, Zaunders JJ, et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 1993, 118, 696-700.
11. 11. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977, 86, 81-92.
12. 12. Cox JD. Response of the trachea and lung to irradiation. In Moss WT, Cox JD, eds. Radiation Oncology: Rationale, Technique, Results. St. Louis, Baltimore, Toronto: CV Mosby, 1989, 285-290.
13. 13. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer 1980, 45, 2744-2753.
14. 14. Rubin P, Cassert GW. Clinical Radiation Pathology, vol 1. Philadelphia, WB Saunders Co., 1968, 423-470.
15. 15. Roach M, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995, 13, 2606-2612.
16. 16. Hayakawa D, Mitsuhashi N, Nakajima N, et al. Radiation therapy for stage I-III epidermoid carcinoma of the lung. Lung Cancer 1992, 8, 213-224.
17. 17. Gross NJ. The pathogenesis of radiation-induced lung damage. Lung 1981, 159, 115-125.
18. 18. Goggle JE, Lambert BE, Moores SR. Radiation effects in the lung. Environ Health Perspect 1986, 70, 261-291.
19. 19. Morgan GW, Breit SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 1995, 31, 361-369.
20. 20. Martel KM, Haken RKT, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994, 28, 575-581.
21. 21. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996, 74, 327-338.
22. 22. Fukuoka M, Niitani H, Suzuki S, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992, 10, 16-20.
23. 23. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83, 1164-1168.
24. 24. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991, 8, 1013-1019.
25. 25. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10, 1225-1229.
26. 26. Kudoh S, Kurihara N, Okishio K, et al. A phase I-II study of weekly irinotecan and simultaneous thoracic radiotherapy for unresectable locally advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 1996, 15, 372.
27. 27. Boothman DA, Wang M, Schea R, et al. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 1992, 24, 939-948.
28. 28. Okishio K, Kudoh S, Kurihara N, et al. Irinotecan enhances the radiosensitivity of lung cancer in vitro (abstract). Proc Am Soc Clin Oncol 1995, 14, 362.
29. 29. Hennequin C, Giocanti N, Balosso J, Favaudon V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 1994, 54, 1720-1728.
30. 30. Tamura K, Takada M, Kawase I, et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 1997, 88, 218-223.